Driehaus Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-201,566
Closed -$5.1M 457
2023
Q2
$5.1M Buy
+201,566
New +$6.28M 0.06% 271
2021
Q4
Sell
-381,302
Closed -$10.6M 457
2021
Q3
$10.6M Buy
381,302
+174,294
+84% +$4.97M 0.13% 220
2021
Q2
$6.14M Sell
207,008
-3,395
-2% -$97.9K 0.08% 268
2021
Q1
$5.88M Sell
210,403
-16,062
-7% -$444K 0.09% 268
2020
Q4
$6.42M Sell
226,465
-356,898
-61% -$9.24M 0.1% 224
2020
Q3
$14.7M Sell
583,363
-166,067
-22% -$4.35M 0.3% 97
2020
Q2
$18.3M Buy
749,430
+8,652
+1% +$171K 0.45% 63
2020
Q1
$11M Buy
740,778
+84,765
+13% +$1.75M 0.37% 77
2019
Q4
$10.6M Buy
+656,013
New +$10.2M 0.28% 97
2016
Q2
Sell
-117,168
Closed -$2.05M 662
2016
Q1
$2.05M Buy
117,168
+39,090
+50% +$796K 0.07% 279
2015
Q4
$2.67M Buy
+78,078
New +$2.71M 0.09% 247
2014
Q4
Sell
-74,289
Closed -$1.44M 605
2014
Q3
$1.44M Sell
74,289
-192,765
-72% -$5.02M 0.05% 391
2014
Q2
$9.08M Sell
267,054
-1,464
-0.5% -$45.9K 0.29% 80
2014
Q1
$8.46M Buy
+268,518
New +$8.39M 0.27% 92

Other funds holding RVNC

Driehaus Capital Management's RVNC Position: Q3 2023 in Review

Driehaus Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 201,566 shares — an estimated $5.1M sold.

Driehaus Capital Management first reported a position in RVNC in Q1 2014 and held it in 14 quarters. The position peaked at $18.3M in Q2 2020. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Driehaus Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Driehaus Capital Management sold 201,566 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $5.1M.
  • Driehaus Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 14 quarters.
  • Driehaus Capital Management's Revance Therapeutics, Inc. position peaked at $18.3M in Q2 2020.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Driehaus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.